LLY

1,014.11

-2.29%↓

JNJ

202.6

-1.25%↓

ABBV

228.53

-0.44%↓

UNH

331.72

-2.21%↓

AZN

90.3

-0.56%↓

LLY

1,014.11

-2.29%↓

JNJ

202.6

-1.25%↓

ABBV

228.53

-0.44%↓

UNH

331.72

-2.21%↓

AZN

90.3

-0.56%↓

LLY

1,014.11

-2.29%↓

JNJ

202.6

-1.25%↓

ABBV

228.53

-0.44%↓

UNH

331.72

-2.21%↓

AZN

90.3

-0.56%↓

LLY

1,014.11

-2.29%↓

JNJ

202.6

-1.25%↓

ABBV

228.53

-0.44%↓

UNH

331.72

-2.21%↓

AZN

90.3

-0.56%↓

LLY

1,014.11

-2.29%↓

JNJ

202.6

-1.25%↓

ABBV

228.53

-0.44%↓

UNH

331.72

-2.21%↓

AZN

90.3

-0.56%↓

Search

West Pharmaceutical Services Inc

Abierto

SectorSanidad

281.68 -0.85

Resumen

Variación precio

24h

Actual

Mínimo

275.4

Máximo

285.06

Métricas clave

By Trading Economics

Ingresos

8.2M

140M

Ventas

38M

804M

P/B

Media del Sector

40.674

80.03

BPA

1.96

Rentabilidad por dividendo

0.3

Margen de beneficios

17.406

Empleados

10,600

EBITDA

19M

217M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+20.68% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.30%

2.29%

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-45M

20B

Apertura anterior

282.53

Cierre anterior

281.68

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

167 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

West Pharmaceutical Services Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 dic 2025, 23:21 UTC

Ganancias
Adquisiciones, fusiones, absorciones

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 dic 2025, 23:14 UTC

Adquisiciones, fusiones, absorciones

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 dic 2025, 22:01 UTC

Principales Movimientos del Mercado

Costco Wholesale Reports Higher Monthly Sales

3 dic 2025, 21:38 UTC

Ganancias

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 dic 2025, 23:59 UTC

Charlas de Mercado

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 dic 2025, 23:49 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 dic 2025, 23:49 UTC

Charlas de Mercado

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 dic 2025, 23:49 UTC

Charlas de Mercado

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 dic 2025, 23:13 UTC

Charlas de Mercado

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 dic 2025, 23:10 UTC

Ganancias

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 dic 2025, 23:08 UTC

Charlas de Mercado

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 dic 2025, 23:06 UTC

Adquisiciones, fusiones, absorciones

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 dic 2025, 22:59 UTC

Adquisiciones, fusiones, absorciones

EQB to Buy PC Financial From Loblaw for About $573.5M

3 dic 2025, 22:45 UTC

Charlas de Mercado

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 dic 2025, 22:20 UTC

Ganancias

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 dic 2025, 22:19 UTC

Ganancias

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 dic 2025, 22:17 UTC

Ganancias

Salesforce Working to Add Voice to Agentforce, CEO Says

3 dic 2025, 22:16 UTC

Ganancias

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 dic 2025, 22:15 UTC

Ganancias

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 dic 2025, 22:10 UTC

Adquisiciones, fusiones, absorciones

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 dic 2025, 22:09 UTC

Adquisiciones, fusiones, absorciones

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 dic 2025, 21:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

3 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

3 dic 2025, 21:49 UTC

Ganancias

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dic 2025, 21:23 UTC

Ganancias

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 dic 2025, 21:19 UTC

Ganancias

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dic 2025, 21:06 UTC

Ganancias

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 dic 2025, 21:04 UTC

Ganancias

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 dic 2025, 21:04 UTC

Ganancias

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 dic 2025, 21:03 UTC

Ganancias

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Comparación entre iguales

Cambio de precio

West Pharmaceutical Services Inc previsión

Precio Objetivo

By TipRanks

20.68% repunte

Estimación a 12 Meses

Media 343.1 USD  20.68%

Máximo 375 USD

Mínimo 285 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para West Pharmaceutical Services Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

10

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

213.26 / 219.27Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

167 / 374 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de West Pharmaceutical Services Inc

West Pharmaceutical Services, Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its products include various primary packaging, containment solutions, reconstitution, and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services, and integrated solutions. The Company’s segments include Proprietary Products and Contract-Manufactured Products. Proprietary Products reportable segment offers proprietary packaging, containment, and drug delivery products, along with analytical lab services and other integrated services. Contract-Manufactured Products segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
help-icon Live chat